Luspatercept - Acceleron Pharma/Celgene Corporation

Drug Profile

Luspatercept - Acceleron Pharma/Celgene Corporation

Alternative Names: ACE-536

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation
  • Class Antianaemics; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Beta-thalassaemia; Myelodysplastic syndromes
  • Phase II Anaemia; Myelofibrosis
  • Preclinical Sickle cell anaemia

Most Recent Events

  • 10 Dec 2017 Pooled efficacy and adverse events data from the phase II trials in Myelodysplastic syndrome presented at the 59th Annual Meeting of the American Society of Hematology (ASH-Hem-2017)
  • 07 Nov 2017 Acceleron and Celgene plans seven clinical trials in 2018
  • 07 Nov 2017 Acceleron plans a phase II trial for Myelofibrosis by year end 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top